​

Vir Bio (VIR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

VIR Stock Forecast

Vir Bio (VIR) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $20.00, with a high of $20.00 and a low of $20.00. This represents a 267.65% increase from the last price of $5.44.

$5 $8 $11 $14 $17 $20 High: $20 Avg: $20 Low: $20 Last Closed Price: $5.44

VIR Stock Rating

Vir Bio stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (72.73%), 3 Hold (27.27%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 3 8 Strong Sell Sell Hold Buy Strong Buy

VIR Price Target Upside V Benchmarks

TypeNameUpside
StockVir Bio267.65%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends

1M3M12M
# Anlaysts--4
Avg Price Target--$22.50
Last Closing Price$5.44$5.44$5.44
Upside/Downside--313.60%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25522--9
Mar, 25522--9
Feb, 25522--9
Jan, 25523--10
Dec, 24423--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 09, 2025Michael UlzMorgan Stanley$20.00$7.89153.49%267.65%
Aug 02, 2024Gena WangBarclays$28.00$9.73187.77%414.71%
Jun 05, 2024Michael UlzMorgan Stanley$15.00$12.6618.48%175.74%
May 21, 2024Gena WangBarclays$27.00$9.69178.64%396.32%
Feb 21, 2023Paul ChoiGoldman Sachs$28.38$25.7410.26%421.69%
May 06, 2022Joseph StringerNeedham$35.00$21.8760.04%543.38%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 28, 2025BarclaysOverweightOverweighthold
Jan 09, 2025Morgan StanleyEqual-WeightOverweightupgrade
Aug 02, 2024NeedhamBuyBuyhold
Aug 02, 2024BarclaysOverweightOverweighthold
Jun 05, 2024Morgan StanleyEqual-WeightEqual-Weighthold
Jun 05, 2024H.C. WainwrightBuyBuyhold
May 21, 2024BarclaysOverweightOverweighthold
May 07, 2024NeedhamBuyBuyhold
Mar 15, 2024J.P. MorganBuyBuyhold
Sep 08, 2023Bank of America SecuritiesNeutraldowngrade

Financial Forecast

EPS Forecast

$-10 $-6 $-2 $2 $6 $10 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.51$4.07$3.89$-4.59$-3.83----
Avg Forecast$-2.39$2.70$4.31$-4.66$-3.88$-3.54$-3.44$-2.78$-1.92
High Forecast$-1.25$5.09$7.98$-3.62$-3.66$-2.59$-2.96$-1.85$0.07
Low Forecast$-4.49$1.42$1.79$-5.42$-3.98$-4.51$-4.01$-3.32$-3.90
Surprise %5.02%50.74%-9.74%-1.50%-1.29%----

Revenue Forecast

$0 $600M $1B $2B $2B $3B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$67.25M$1.09B$1.58B$86.18M$74.20M----
Avg Forecast$79.35M$905.58M$1.71B$79.68M$68.66M$30.36M$32.45M$84.42M$289.68M
High Forecast$133.22M$1.52B$2.83B$105.05M$95.87M$54.58M$33.17M$151.76M$520.71M
Low Forecast$50.29M$573.97M$942.29M$68.07M$58.31M$6.20M$31.74M$17.23M$59.13M
Surprise %-15.25%20.04%-7.73%8.16%8.08%----

Net Income Forecast

$-2B $-1B $-500M $0 $500M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-298.67M$528.58M$515.84M$-615.06M$-521.96M----
Avg Forecast$-169.63M$341.01M$396.47M$-615.06M$-533.34M$-535.68M$-467.09M$-346.71M$-256.89M
High Forecast$-135.70M$669.82M$719.43M$-114.04M$-491.49M$-347.75M$-396.77M$-247.65M$8.90M
Low Forecast$-203.56M$12.20M$73.51M$-1.12B$-533.99M$-604.56M$-537.42M$-445.77M$-523.24M
Surprise %76.07%55.00%30.11%--2.13%----

VIR Forecast FAQ

Is Vir Bio stock a buy?

Vir Bio stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Vir Bio is a favorable investment for most analysts.

What is Vir Bio's price target?

Vir Bio's price target, set by 11 Wall Street analysts, averages $20 over the next 12 months. The price target range spans from $20 at the low end to $20 at the high end, suggesting a potential 267.65% change from the previous closing price of $5.44.

How does Vir Bio stock forecast compare to its benchmarks?

Vir Bio's stock forecast shows a 267.65% upside, outperforming the average forecast for the healthcare stocks sector (33.91%) and outperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for Vir Bio over the past three months?

  • April 2025: 55.56% Strong Buy, 22.22% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 55.56% Strong Buy, 22.22% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 55.56% Strong Buy, 22.22% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.

What is Vir Bio’s EPS forecast?

Vir Bio's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.54, marking a -7.57% decrease from the reported $-3.83 in 2024. Estimates for the following years are $-3.44 in 2026, $-2.78 in 2027, and $-1.92 in 2028.

What is Vir Bio’s revenue forecast?

Vir Bio's average annual revenue forecast for its fiscal year ending in December 2025 is $30.36M, reflecting a -59.08% decrease from the reported $74.2M in 2024. The forecast for 2026 is $32.45M, followed by $84.42M for 2027, and $289.68M for 2028.

What is Vir Bio’s net income forecast?

Vir Bio's net income forecast for the fiscal year ending in December 2025 stands at $-536M, representing an 2.63% increase from the reported $-522M in 2024. Projections indicate $-467M in 2026, $-347M in 2027, and $-257M in 2028.